Catalyst Wire Dossier Catalyst Wire Dossier

CSE-1034

ceftriaxone+ sulbactam+ EDTA · Venus Remedies Limited
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CSE-1034, covering 2019-08-29 to 2019-08-29. Get the full timeline:

Most recent: Clinical Trial Update: CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria [Phase 3]

See pricing